The process in which the insulin is administered, absorbed, distributed, and eliminated from the body differs significantly. The patients may use different body regions for injection of the insulin, for example, abdomen, deltoid, gluteus, and thigh. Insulin differs in the mode of injection into the bloodstream, for example, intravenous and subcutaneous injection of insulin has been established to be effective as the insulin is easily absorbed. This is mainly used to administer Aspart and Lispro insulin. The insulin Glulisine is easily absorbed into the blood and eliminated in the liver. On the other hand, the glucose-lowering effect of insulin Degludec has the same effect when administered through the abdomen, upper arm, or thigh sites, but they were absorbed slowly into the blood. The human regular insulin suspension and human insulin isophane suspension had a different absorption rate. The distribution and elimination of the insulin from the kidney and liver are similar (Home, 2012).
There are various types of endocrine disorders today, but the most common one is diabetes mellitus. It is a disorder that occurs when the blood sugar is not produced or used efficiently in the body. There are three major types, including Type I diabetes, which occurs when insulin is not provided in the body. Patients with type I diabetes are administered with artificial insulin. Type 2 diabetes happens when insulin is not utilized properly in the body; it is common among middle-aged and older people and is mainly linked with obesity. Gestational diabetes can occur in pregnant women when their bodies are not sensitive to insulin. Treatment of diabetes includes observing the blood sugar levels with a combination of medications, exercise, and diet (American Diabetes Association, 2013).
Delegate your assignment to our experts and they will do the rest.
References
American Diabetes Association. (2013). Diagnosis and classification of diabetes mellitus. Diabetes care , 36 (Supplement 1), S67-S74.
Home, P. D. (2012). The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism , 14 (9), 780-788.
